## SUDDEN CORONARY DEATH Page 23 of 308

Row	Study PMID	Study Name	Outcome	Outcome Definition	Population Type	Population	Subgroup	Cases Total/N Total (Rate %)	Followup	n3 FA	n3 measure
2	Albert 2005 16301356	Nurses' Health Study	SCD	nd	Healthy	Healthy 34-59 yo female nurses	All	206/76763 (0.27)	18 y	ALA	Intake
3	Albert 2005 16301356	Nurses' Health Study	SCD	nd	Healthy	Healthy 34-59 yo female nurses	All	206/76763 (0.27)	18 y	ALA	Intake
4	Albert 2005 16301356	Nurses' Health Study	SCD	nd	Healthy	Healthy 34-59 yo female nurses	All	206/76763 (0.27)	18 y	ALA	Intake
5	Albert 2005 16301356	Nurses' Health Study	SCD	nd	Healthy	Healthy 34-59 yo female nurses	All	206/76763 (0.27)	18 y	ALA	Intake
6	Albert 2005 16301356	Nurses' Health Study	SCD	nd	Healthy	Healthy 34-59 yo female nurses	All	206/76763 (0.27)	18 y	ALA	Intake
7	Fretts 2014 25159901	Cardiovascular Health Study	SCD	Arrythmic death	Healthy	Healthy age >= 65y	All	135/2583 (5.2)	12y	ALA	Intake
8	Fretts 2014 25159901	Cardiovascular Health Study	SCD	Arrythmic death	Healthy	Healthy age >= 65y	All	135/2583 (5.2)	12y	ALA	Intake
9	Fretts 2014 25159901	Cardiovascular Health Study	SCD	Arrythmic death	Healthy	Healthy age >= 65y	All	135/2583 (5.2)	12y	ALA	Intake
10	Fretts 2014 25159901	Cardiovascular Health Study	SCD	Arrythmic death	Healthy	Healthy age >= 65y	All	135/2583 (5.2)	12y	ALA	Intake
11	Fretts 2014 25159901	Cardiovascular Health Study	SCD	Arrythmic death	Healthy	Healthy age >= 65y	All	135/2583 (5.2)	12y	ALA	Intake
12	Fretts 2014 25159901	Cardiovascular Health Study	SCD	Arrythmic death	Healthy	Healthy age >= 65y	All	170/2709 (6.3)	16y	ALA	Plasma
13	Fretts 2014 25159901	Cardiovascular Health Study	SCD	Arrythmic death	Healthy	Healthy age >= 65y	All	170/2709 (6.3)	16y	ALA	Plasma
14	Fretts 2014 25159901	Cardiovascular Health Study	SCD	Arrythmic death	Healthy	Healthy age >= 65y	All	170/2709 (6.3)	16y	ALA	Plasma
15	Fretts 2014 25159901	Cardiovascular Health Study	SCD	Arrythmic death	Healthy	Healthy age >= 65y	All	170/2709 (6.3)	16y	ALA	Plasma
16	Fretts 2014 25159901	Cardiovascular Health Study	SCD	Arrythmic death	Healthy	Healthy age >= 65y	All	170/2709 (6.3)	16y	ALA	Plasma
17	Mozaffarian 2013 23546563	Cardiovascular Health Study	SCD	Arrythmic death	Healthy	Healthy age >= 65y	All	194/3941 (4.92)	16y	All n-3	Plasma
18	Mozaffarian 2013 23546563	Cardiovascular Health Study	SCD	Arrythmic death	Healthy	Healthy age >= 65y	All	194/3941 (4.92)	16y	All n-3	Plasma
19	Mozaffarian 2013 23546563	Cardiovascular Health Study	SCD	Arrythmic death	Healthy	Healthy age >= 65y	All	194/3941 (4.92)	16y	All n-3	Plasma
20	Mozaffarian 2013 23546563	Cardiovascular Health Study	SCD	Arrythmic death	Healthy	Healthy age >= 65y	All	194/3941 (4.92)	16y	All n-3	Plasma
21	Mozaffarian 2013 23546563	Cardiovascular Health Study	SCD	Arrythmic death	Healthy	Healthy age >= 65y	All	194/3941 (4.92)	16y	All n-3	Plasma

# SUDDEN CORONARY DEATH Page 24 of 308

Row	Study PMID	Supplement	Adjustments
2	Albert 2005 16301356	no	age, time periods, smoking status (never, past, curent), BMI (<22, 22-22.9, 23-24.9, 25-28.9, 29+ kg/m2), alcohol intake (0, <5, 5-14, 15+), menopausal status and postmenopausal hormone use, vigorous to moderate activity (<1, 1-1.9, 2-3.9, 4-6.9, 7+ hours/week), number of times aspirin was used per week (<1, 1-2, 3-6, 7-14, 15+), multivitamin use (yes vs. no), vitamin E supplement use (yes vs. no), history of HTN (yes vs. no), hypercholesterolemia (yes vs. no), diabetes (yes vs. no), family history of MI (no, before age 60 y, after age 60 y), history of prior CVD (yes vs. no)
3	Albert 2005 16301356	no	age, time periods, smoking status (never, past, curent), BMI (<22, 22-22.9, 23-24.9, 25-28.9, 29+ kg/m2), alcohol intake (0, <5, 5-14, 15+), menopausal status and postmenopausal hormone use, vigorous to moderate activity (<1, 1-1.9, 2-3.9, 4-6.9, 7+ hours/week), number of times aspirin was used per week (<1, 1-2, 3-6, 7-14, 15+), multivitamin use (yes vs. no), vitamin E supplement use (yes vs. no), history of HTN (yes vs. no), hypercholesterolemia (yes vs. no), diabetes (yes vs. no), family history of MI (no, before age 60 y, after age 60 y), history of prior CVD (yes vs. no)
4	Albert 2005 16301356	no	age, time periods, smoking status (never, past, curent), BMI (<22, 22-22.9, 23-24.9, 25-28.9, 29+ kg/m2), alcohol intake (0, <5, 5-14, 15+), menopausal status and postmenopausal hormone use, vigorous to moderate activity (<1, 1-1.9, 2-3.9, 4-6.9, 7+ hours/week), number of times aspirin was used per week (<1, 1-2, 3-6, 7-14, 15+), multivitamin use (yes vs. no), vitamin E supplement use (yes vs. no), history of HTN (yes vs. no), hypercholesterolemia (yes vs. no), diabetes (yes vs. no), family history of MI (no, before age 60 y, after age 60 y), history of prior CVD (yes vs. no)
5	Albert 2005 16301356	no	age, time periods, smoking status (never, past, curent), BMI (<22, 22-22.9, 23-24.9, 25-28.9, 29+ kg/m2), alcohol intake (0, <5, 5-14, 15+), menopausal status and postmenopausal hormone use, vigorous to moderate activity (<1, 1-1.9, 2-3.9, 4-6.9, 7+ hours/week), number of times aspirin was used per week (<1, 1-2, 3-6, 7-14, 15+), multivitamin use (yes vs. no), vitamin E supplement use (yes vs. no), history of HTN (yes vs. no), hypercholesterolemia (yes vs. no), diabetes (yes vs. no), family history of MI (no, before age 60 y, after age 60 y), history of prior CVD (yes vs. no)
6	Albert 2005 16301356	no	age, time periods, smoking status (never, past, curent), BMI (<22, 22-22.9, 23-24.9, 25-28.9, 29+ kg/m²), alcohol intake (0, <5, 5-14, 15+), menopausal status and postmenopausal hormone use, vigorous to moderate activity (<1, 1-1.9, 2-3.9, 4-6.9, 7+ hours/week), number of times aspirin was used per week (<1, 1-2, 3-6, 7-14, 15+), multivitamin use (yes vs. no), vitamin E supplement use (yes vs. no), history of HTN (yes vs. no), hypercholesterolemia (yes vs. no), diabetes (yes vs. no), family history of MI (no, before age 60 y, after age 60 y), history of prior CVD (yes vs. no)
7	Fretts 2014 25159901	no	age, sex, race, enrolment site, education, smoking status, diabetes, BMI, waist circumference, physical activity, alcohol consumption and treated hypertension.
8	Fretts 2014 25159901	no	age, sex, race, enrolment site, education, smoking status, diabetes, BMI, waist circumference, physical activity, alcohol consumption and treated hypertension.
9	Fretts 2014 25159901	no	age, sex, race, enrolment site, education, smoking status, diabetes, BMI, waist circumference, physical activity, alcohol consumption and treated hypertension.
10	Fretts 2014 25159901	no	age, sex, race, enrolment site, education, smoking status, diabetes, BMI, waist circumference, physical activity, alcohol consumption and treated hypertension.
11	Fretts 2014 25159901	no	age, sex, race, enrolment site, education, smoking status, diabetes, BMI, waist circumference, physical activity, alcohol consumption and treated hypertension.
12	Fretts 2014 25159901	no	age, sex, race, enrolment site, education, smoking status, diabetes, BMI, waist circumference, physical activity, alcohol consumption and treated hypertension.
13	Fretts 2014 25159901	no	age, sex, race, enrolment site, education, smoking status, diabetes, BMI, waist circumference, physical activity, alcohol consumption and treated hypertension.
14	Fretts 2014 25159901	no	age, sex, race, enrolment site, education, smoking status, diabetes, BMI, waist circumference, physical activity, alcohol consumption and treated hypertension.
15	Fretts 2014 25159901	no	age, sex, race, enrolment site, education, smoking status, diabetes, BMI, waist circumference, physical activity, alcohol consumption and treated hypertension.
16	Fretts 2014 25159901	no	age, sex, race, enrolment site, education, smoking status, diabetes, BMI, waist circumference, physical activity, alcohol consumption and treated hypertension.
17	Mozaffarian 2013 23546563	no	Adjusted for age (years), sex, race (white, nonwhite), education( <high (1994–96,="" (4="" (6="" (cm),="" (kg="" (mcal="" (never,="" (yes,="" 2007–10),="" acid="" activity="" alcohol="" and="" atrial="" batch="" body="" categories).<="" circumference="" college="" college,="" current),="" diabetes="" drug-treated="" enrollment="" fatty="" fibrillation="" former,="" graduate),="" high="" hypertension="" index="" leisure-time="" m2),="" mass="" measurement="" no),="" physical="" prevalent="" school,="" site="" sites),="" smoking="" some="" td="" use="" waist="" week),=""></high>
18	Mozaffarian 2013 23546563	no	Adjusted for age (years), sex, race (white, nonwhite), education( <high (1994–96,="" (4="" (6="" (cm),="" (kg="" (mcal="" (never,="" (yes,="" 2007–10),="" acid="" activity="" alcohol="" and="" atrial="" batch="" body="" categories).<="" circumference="" college="" college,="" current),="" diabetes="" drug-treated="" enrollment="" fatty="" fibrillation="" former,="" graduate),="" high="" hypertension="" index="" leisure-time="" m2),="" mass="" measurement="" no),="" physical="" prevalent="" school,="" site="" sites),="" smoking="" some="" td="" use="" waist="" week),=""></high>
19	Mozaffarian 2013 23546563	no	Adjusted for age (years), sex, race (white, nonwhite), education(-high school, high school, some college, college graduate), enrollment site (4 sites), fatty acid measurement batch (1994–96, 2007–10), smoking (never, former, current), prevalent diabetes (yes, no), prevalent atrial fibrillation (yes, no), prevalent drug-treated hypertension (yes, no), leisure-time physical activity (mcal/week), body mass index (kg/m2), waist circumference (cm), and alcohol use (6 categories).
20	Mozaffarian 2013 23546563	no	Adjusted for age (years), sex, race (white, nonwhite), education(-high school, high school, some college, college graduate), enrollment site (4 sites), fatty acid measurement batch (1994–96, 2007–10), smoking (never, former, current), prevalent diabetes (yes, no), prevalent atrial fibrillation (yes, no), prevalent drug-treated hypertension (yes, no), leisure-time physical activity (mcal/week), body mass index (kg/m2), waist circumference (cm), and alcohol use (6 categories).
21	Mozaffarian 2013 23546563	no	Adjusted for age (years), sex, race (white, nonwhite), education(-high school, high school, some college, college graduate), enrollment site (4 sites), fatty acid measurement batch (1994–96, 2007–10), smoking (never, former, current), prevalent diabetes (yes, no), prevalent atrial fibrillation (yes, no), prevalent drug-treated hypertension (yes, no), leisure-time physical activity (mcal/week), body mass index (kg/m2), waist circumference (cm), and alcohol use (6 categories).

Row	Study PMID	Quantile	n3 units	Quantile low	Quantile median	Quantile high	Metric	n Cases	N quantile	Person Years	Estimate	CI low	CI high	Comparison	P value
2	Albert 2005 16301356	Qt1	% kcal	nd	0.37	nd	RR	54		265219	Reference group			P trend	0.02
3	Albert 2005 16301356	Qt2	nd	nd	0.45	nd	RR	44		264770	0.85	0.57	1.27		
4	Albert 2005 16301356	Qt3	nd	nd	0.52	nd	RR	40		264962	0.76	0.5	1.16		
5	Albert 2005 16301356	Qt4	nd	nd	0.6	nd	RR	32		264647	0.63	0.4	0.98		
6	Albert 2005 16301356	Qt5	nd	nd	0.74	nd	RR	36		264520	0.63	0.41	0.98		
7	Fretts 2014 25159901	Qt1	% fat intake	0.39	1.33	1.45	HR	30	nd	4875	Reference group			P trend	0.42
8	Fretts 2014 25159901	Qt2	% fat intake	1.45	1.56	1.65	HR	28	nd	4987	0.93	0.55	1.58		
9	Fretts 2014 25159901	Qt3	% fat intake	1.65	1.76	1.87	HR	23	nd	5096	0.8	0.46	1.38		
10	Fretts 2014 25159901	Qt4	% fat intake	1.87	2	2.17	HR	34	nd	5291	1.1	0.66	1.84		
11	Fretts 2014 25159901	Qt5	% fat intake	2.17	2.44	4.88	HR	20	nd	5600	0.68	0.38	1.23		
12	Fretts 2014 25159901	Qt1	% FA	0.05	0.09	0.11	HR	35	nd	6483	Reference group			P trend	0.99
13	Fretts 2014 25159901	Qt2	% FA	0.11	0.12	0.13	HR	30	nd	6025	1.02	0.62	1.67		
14	Fretts 2014 25159901	Qt3	% FA	0.13	0.14	0.15	HR	38	nd	6315	1.23	0.76	1.99		
15	Fretts 2014 25159901	Qt4	% FA	0.15	0.17	0.19	HR	34	nd	6352	1.05	0.64	1.71		
16	Fretts 2014 25159901	Qt5	% FA	0.19	0.22	0.47	HR	33	nd	6936	0.98	0.6	1.62		
17	Mozaffarian 2013 23546563	Qt1	% FA	nd	3.17	nd	HR	nd	nd	nd	Reference group			P trend	0.008
18	Mozaffarian 2013 23546563	Qt2	% FA	nd	3.72	nd	HR	nd	nd	nd	0.79	0.5	1.24		
19	Mozaffarian 2013 23546563	Qt3	% FA	nd	4.21	nd	HR	nd	nd	nd	1.07	0.7	1.63		
20	Mozaffarian 2013 23546563	Qt4	% FA	nd	4.8	nd	HR	nd	nd	nd	0.68	0.42	1.1		
21	Mozaffarian 2013 23546563	Qt5	% FA	nd	6.04	nd	HR	nd	nd	nd	0.52	0.31	0.86		

	0										
Row	Study PMID	Study Name	Outcome	Outcome Definition	Population Type	Population	Subgroup	Cases Total/N Total (Rate %)	Followup	n3 FA	n3 measure
22	Mozaffarian 2013 23546563	Cardiovascular Health Study	SCD	Arrythmic death	Healthy	Healthy age >= 65y	All	194/3941 (4.92)	16y	DHA	Plasma
23	Mozaffarian 2013 23546563	Cardiovascular Health Study	SCD	Arrythmic death	Healthy	Healthy age >= 65y	All	194/3941 (4.92)	16y	DHA	Plasma
24	Mozaffarian 2013 23546563	Cardiovascular Health Study	SCD	Arrythmic death	Healthy	Healthy age >= 65y	All	194/3941 (4.92)	16y	DHA	Plasma
25	Mozaffarian 2013 23546563	Cardiovascular Health Study	SCD	Arrythmic death	Healthy	Healthy age >= 65y	All	194/3941 (4.92)	16y	DHA	Plasma
26	Mozaffarian 2013 23546563	Cardiovascular Health Study	SCD	Arrythmic death	Healthy	Healthy age >= 65y	All	194/3941 (4.92)	16y	DHA	Plasma
27	Mozaffarian 2013 23546563	Cardiovascular Health Study	SCD	Arrythmic death	Healthy	Healthy age >= 65y	All	194/3941 (4.92)	16y	DPA	Plasma
28	Mozaffarian 2013 23546563	Cardiovascular Health Study	SCD	Arrythmic death	Healthy	Healthy age >= 65y	All	194/3941 (4.92)	16y	DPA	Plasma
29	Mozaffarian 2013 23546563	Cardiovascular Health Study	SCD	Arrythmic death	Healthy	Healthy age >= 65y	All	194/3941 (4.92)	16y	DPA	Plasma
30	Mozaffarian 2013 23546563	Cardiovascular Health Study	SCD	Arrythmic death	Healthy	Healthy age >= 65y	All	194/3941 (4.92)	16y	DPA	Plasma
31	Mozaffarian 2013 23546563	Cardiovascular Health Study	SCD	Arrythmic death	Healthy	Healthy age >= 65y	All	194/3941 (4.92)	16y	DPA	Plasma
32	Mozaffarian 2013 23546563	Cardiovascular Health Study	SCD	Arrythmic death	Healthy	Healthy age >= 65y	All	194/3941 (4.92)	16y	EPA	Plasma
33	Mozaffarian 2013 23546563	Cardiovascular Health Study	SCD	Arrythmic death	Healthy	Healthy age >= 65y	All	194/3941 (4.92)	16y	EPA	Plasma
34	Mozaffarian 2013 23546563	Cardiovascular Health Study	SCD	Arrythmic death	Healthy	Healthy age >= 65y	All	194/3941 (4.92)	16y	EPA	Plasma
35	Mozaffarian 2013 23546563	Cardiovascular Health Study	SCD	Arrythmic death	Healthy	Healthy age >= 65y	All	194/3941 (4.92)	16y	EPA	Plasma
36	Mozaffarian 2013 23546563	Cardiovascular Health Study	SCD	Arrythmic death	Healthy	Healthy age >= 65y	All	194/3941 (4.92)	16y	EPA	Plasma
37	Iso 2006 16401768	Japan Public Health Center- Based Study - Cohort I	SCD	nd	Healthy	Healthy 40-59	All	37/41578 (0.09)	11.5 y	EPA+DHA	Intake
38	Iso 2006 16401768	Japan Public Health Center- Based Study - Cohort I	SCD	nd	Healthy	Healthy 40-59	All	37/41578 (0.09)	11.5 y	EPA+DHA	Intake

# SUDDEN CORONARY DEATH Page 27 of 308

(4 sites), fatty acid measurement batch (1994–96, 2007–10), smoking urre-time physical activity (mcal/week), body mass index (kg/m2), waist (4 sites), fatty acid measurement batch (1994–96, 2007–10), smoking urre-time physical activity (mcal/week), body mass index (kg/m2), waist (4 sites), fatty acid measurement batch (1994–96, 2007–10), smoking urre-time physical activity (mcal/week), body mass index (kg/m2), waist (4 sites), fatty acid measurement batch (1994–96, 2007–10), smoking urre-time physical activity (mcal/week), body mass index (kg/m2), waist
(4 sites), fatty acid measurement batch (1994–96, 2007–10), smoking urre-time physical activity (mcal/week), body mass index (kg/m2), waist (4 sites), fatty acid measurement batch (1994–96, 2007–10), smoking
ure-time physical activity (mcal/week), body mass index (kg/m2), waist  (4 sites), fatty acid measurement batch (1994–96, 2007–10), smoking
(4 sites), fatty acid measurement batch (1994–96, 2007–10), smoking sure-time physical activity (mcal/week), body mass index (kg/m2), waist
(4 sites), fatty acid measurement batch (1994–96, 2007–10), smoking sure-time physical activity (mcal/week), body mass index (kg/m2), waist
(4 sites), fatty acid measurement batch (1994–96, 2007–10), smoking sure-time physical activity (mcal/week), body mass index (kg/m2), waist
(4 sites), fatty acid measurement batch (1994–96, 2007–10), smoking sure-time physical activity (mcal/week), body mass index (kg/m2), waist
(4 sites), fatty acid measurement batch (1994–96, 2007–10), smoking sure-time physical activity (mcal/week), body mass index (kg/m2), waist
(4 sites), fatty acid measurement batch (1994–96, 2007–10), smoking sure-time physical activity (mcal/week), body mass index (kg/m2), waist
(4 sites), fatty acid measurement batch (1994–96, 2007–10), smoking sure-time physical activity (mcal/week), body mass index (kg/m2), waist
(4 sites), fatty acid measurement batch (1994–96, 2007–10), smoking sure-time physical activity (mcal/week), body mass index (kg/m2), waist
(4 sites), fatty acid measurement batch (1994–96, 2007–10), smoking urre-time physical activity (mcal/week), body mass index (kg/m2), waist
(4 sites), fatty acid measurement batch (1994–96, 2007–10), smoking sure-time physical activity (mcal/week), body mass index (kg/m2), waist
(4 sites), fatty acid measurement batch (1994–96, 2007–10), smoking sure-time physical activity (mcal/week), body mass index (kg/m2), waist
s, saturated fat,
s, saturated fat,

Row	Study PMID	Quantile	n3 units	Quantile low	Quantile median	Quantile high	Metric	n Cases	N quantile	Person Years	Estimate	CI low	CI high	Comparison	P value
22	Mozaffarian 2013 23546563	Qt1	% FA	nd	1.95	nd	HR	nd	nd	nd	Reference group			P trend	0.028
23	Mozaffarian 2013 23546563	Qt2	% FA	nd	2.44	nd	HR	nd	nd	nd	0.97	0.62	1.51		
24	Mozaffarian 2013 23546563	Qt3	% FA	nd	2.87	nd	HR	nd	nd	nd	0.85	0.54	1.33		
25	Mozaffarian 2013 23546563	Qt4	% FA	nd	3.36	nd	HR	nd	nd	nd	0.92	0.59	1.44		
26	Mozaffarian 2013 23546563	Qt5	% FA	nd	4.34	nd	HR	nd	nd	nd	0.55	0.33	0.93		
27	Mozaffarian 2013 23546563	Qt1	% FA	nd	0.63	nd	HR	nd	nd	nd	Reference group			P trend	0.39
28	Mozaffarian 2013 23546563	Qt2	% FA	nd	0.75	nd	HR	nd	nd	nd	0.79	0.49	1.27		
29	Mozaffarian 2013 23546563	Qt3	% FA	nd	0.82	nd	HR	nd	nd	nd	1.32	0.85	2.04		
30	Mozaffarian 2013 23546563	Qt4	% FA	nd	0.91	nd	HR	nd	nd	nd	0.83	0.52	1.34		
31	Mozaffarian 2013 23546563	Qt5	% FA	nd	1.04	nd	HR	nd	nd	nd	0.79	0.49	1.3		
32	Mozaffarian 2013 23546563	Qt1	% FA	nd	0.3	nd	HR	nd	nd	nd	Reference group			P trend	0.22
33	Mozaffarian 2013 23546563	Qt2	% FA	nd	0.41	nd	HR	nd	nd	nd	0.96	0.62	1.5		
34	Mozaffarian 2013 23546563	Qt3	% FA	nd	0.51	nd	HR	nd	nd	nd	0.83	0.53	1.31		
35	Mozaffarian 2013 23546563	Qt4	% FA	nd	0.64	nd	HR	nd	nd	nd	0.82	0.52	1.29		
36	Mozaffarian 2013 23546563	Qt5	% FA	nd	0.92	nd	HR	nd	nd	nd	0.76	0.47	1.23		
37	Iso 2006 16401768	Qt1	g/d	nd	0.3 (mean)	nd	HR	7	nd	102711	Reference group			P trend	0.12
38	Iso 2006 16401768	Qt2	g/d	nd	0.6 (mean)	nd	HR	0	nd	95861	ND				

## SUDDEN CORONARY DEATH Page 29 of 308

Row	Study PMID	Study Name	Outcome	Outcome Definition	Population Type	Population	Subgroup	Cases Total/N Total (Rate %)	Followup	n3 FA	n3 measure
39	Iso 2006 16401768	Japan Public Health Center- Based Study - Cohort I	SCD	nd	Healthy	Healthy 40-59	All	37/41578 (0.09)	11.5 y	EPA+DHA	Intake
40	Iso 2006 16401768	Japan Public Health Center- Based Study - Cohort I	SCD	nd	Healthy	Healthy 40-59	All	37/41578 (0.09)	11.5 y	EPA+DHA	Intake
41	Iso 2006 16401768	Japan Public Health Center- Based Study - Cohort I	SCD	nd	Healthy	Healthy 40-59	All	37/41578 (0.09)	11.5 y	EPA+DHA	Intake
42	Albert 1998 942039	Physician's Health Study	SCD	sudden cardiac death	Healthy	US male physicians	All	133/20551 (0.65)	11 y	All n-3	Intake
43	Albert 1998 942039	Physician's Health Study	SCD	sudden cardiac death	Healthy	US male physicians	All	133/20551 (0.65)	11 y	All n-3	Intake
44	Albert 1998 942039	Physician's Health Study	SCD	sudden cardiac death	Healthy	US male physicians	All	133/20551 (0.65)	11 y	All n-3	Intake
45	Albert 1998 942039	Physician's Health Study	SCD	sudden cardiac death	Healthy	US male physicians	All	133/20551 (0.65)	11 y	All n-3	Intake
46	Albert 1998 942039	Physician's Health Study	SCD	sudden cardiac death	Healthy	US male physicians	All	133/20551 (0.65)	11 y	All n-3	Intake
48	Subgroup analyses										
49	Albert 2005 16301356	Nurses' Health Study	SCD	nd	CVD	CVD (women)	CVD	47/nd (0.3)	18 y	ALA	Intake
50	Albert 2005 16301356	Nurses' Health Study	SCD	nd	CVD	CVD (women)	CVD	47/nd (0.3)	18 y	ALA	Intake
51	Albert 2005 16301356	Nurses' Health Study	SCD	nd	CVD	CVD (women)	CVD	47/nd (0.3)	18 y	ALA	Intake
52	Albert 2005 16301356	Nurses' Health Study	SCD	nd	CVD	CVD (women)	CVD	47/nd (0.3)	18 y	ALA	Intake
53	Albert 2005 16301356	Nurses' Health Study	SCD	nd	CVD	CVD (women)	CVD	47/nd (0.3)	18 y	ALA	Intake
54	Albert 2005 16301356	Nurses' Health Study	SCD	nd	Healthy	Healthy 34-59 yo female nurses	No CVD	159/nd (0.3)	18 y	ALA	Intake
55	Albert 2005 16301356	Nurses' Health Study	SCD	nd	Healthy	Healthy 34-59 yo female nurses	No CVD	159/nd (0.3)	18 y	ALA	Intake
56	Albert 2005 16301356	Nurses' Health Study	SCD	nd	Healthy	Healthy 34-59 yo female nurses	No CVD	159/nd (0.3)	18 y	ALA	Intake
57	Albert 2005 16301356	Nurses' Health Study	SCD	nd	Healthy	Healthy 34-59 yo female nurses	No CVD	159/nd (0.3)	18 y	ALA	Intake

## SUDDEN CORONARY DEATH Page 30 of 308

Row	Study PMID	Supplement	Adjustments
39	Iso 2006 16401768	No	age; sex; cigarette smoking; alcohol intake; body mass index; histories of hypertension and diabetes; medication use for hypercholesterolemia; education level; sports at leisure time; quintiles of dietary intake of fruits, vegetables, saturated fat, monounsaturated fat, cholesterol, and total energy; and PHC.
40	Iso 2006 16401768	No	age; sex; cigarette smoking; alcohol intake; body mass index; histories of hypertension and diabetes; medication use for hypercholesterolemia; education level; sports at leisure time; quintiles of dietary intake of fruits, vegetables, saturated fat, monounsaturated fat, n6 polyunsaturated fat, cholesterol, and total energy; and PHC.
<b>4</b> 1	Iso 2006 16401768	No	age; sex; cigarette smoking; alcohol intake; body mass index; histories of hypertension and diabetes; medication use for hypercholesterolemia; education level; sports at leisure time; quintiles of dietary intake of fruits, vegetables, saturated fat, monounsaturated fat, n6 polyunsaturated fat, cholesterol, and total energy; and PHC.
12	Albert 1998 942039	explicitly excluded fish oil supplements	age, aspirin and bea carotene treatment assignment, evidence of CVD prior to 12-month questionnaire, BMI, smoking status, history of diabetes, history of hypertension, history of hypercholesterolemia, alcohol consumption, and vitamin E, vitamin C, and multivitamin use.
43	Albert 1998 942039	explicitly excluded fish oil supplements	age, aspirin and bea carotene treatment assignment, evidence of CVD prior to 12-month questionnaire, BMI, smoking status, history of diabetes, history of hypertension, history of hypercholesterolemia, alcohol consumption, and vitamin E, vitamin C, and multivitamin use.
14	Albert 1998 942039	explicitly excluded fish oil supplements	age, aspirin and bea carotene treatment assignment, evidence of CVD prior to 12-month questionnaire, BMI, smoking status, history of diabetes, history of hypertension, history of hypercholesterolemia, alcohol consumption, and vitamin E, vitamin C, and multivitamin use.
<b>1</b> 5	Albert 1998 942039	explicitly excluded fish oil supplements	age, aspirin and bea carotene treatment assignment, evidence of CVD prior to 12-month questionnaire, BMI, smoking status, history of diabetes, history of hypertension, history of hypercholesterolemia, alcohol consumption, and vitamin E, vitamin C, and multivitamin use.
46	Albert 1998 942039	explicitly excluded fish oil supplements	age, aspirin and bea carotene treatment assignment, evidence of CVD prior to 12-month questionnaire, BMI, smoking status, history of diabetes, history of hypertension, history of hypercholesterolemia, alcohol consumption, and vitamin E, vitamin C, and multivitamin use.
0	O. d		
<b>49</b>	Subgroup analyses Albert 2005 16301356	no	age, time periods, smoking status (never, past, curent), BMI (<22, 22-22.9, 23-24.9, 25-28.9, 29+ kg/m2), alcohol intake (0, <5, 5-14, 15+), menopausal status and postmenopausal hormone use, vigorous to moderate activity (<1, 1-1.9, 2-3.9, 4-6.9, 7+ hours/week), number of times aspirin was used per week (<1, 1-2, 3-6, 7-14, 15+), multivitamin use (yes vs. no), vitamin E supplement use (yes vs. no), history of HTN (yes vs. no), hypercholesterolemia (yes vs. no), diabetes (yes vs. no), family history of MI (no, before age 60 y, after age 60 y), history of prior CVD (yes vs. no)
50	Albert 2005 16301356	no	age, time periods, smoking status (never, past, curent), BMI (<22, 22-22.9, 23-24.9, 25-28.9, 29+ kg/m2), alcohol intake (0, <5, 5-14, 15+), menopausal status and postmenopausal hormone use, vigorous to moderate activity (<1, 1-1.9, 2-3.9, 4-6.9, 7+ hours/week), number of times aspirin was used per week (<1, 1-2, 3-6, 7-14, 15+), multivitamin use (yes vs. no), vitamin E supplement use (yes vs. no), history of HTN (yes vs. no), hypercholesterolemia (yes vs. no), diabetes (yes vs. no), family history of MI (no, before age 60 y), after age 60 y), history of prior CVD (yes vs. no)
51	Albert 2005 16301356	no	age, time periods, smoking status (never, past, curent), BMI (<22, 22-22.9, 23-24.9, 25-28.9, 29+ kg/m2), alcohol intake (0, <5, 5-14, 15+), menopausal status and postmenopausal hormone use, vigorous to moderate activity (<1, 1-1.9, 2-3.9, 4-6.9, 7+ hours/week), number of times aspirin was used per week (<1, 1-2, 3-6, 7-14, 15+), multivitamin use (yes vs. no), vitamin E supplement use (yes vs. no), history of HTN (yes vs. no), hypercholesterolemia (yes vs. no), diabetes (yes vs. no), family history of MI (no, before age 60 y, after age 60 y), history of prior CVD (yes vs. no)
52	Albert 2005 16301356	no	age, time periods, smoking status (never, past, curent), BMI (<22, 22-22.9, 23-24.9, 25-28.9, 29+ kg/m2), alcohol intake (0, <5, 5-14, 15+), menopausal status and postmenopausal hormone use, vigorous to moderate activity (<1, 1-1.9, 2-3.9, 4-6.9, 7+ hours/week), number of times aspirin was used per week (<1, 1-2, 3-6, 7-14, 15+), multivitamin use (yes vs. no), vitamin E supplement use (yes vs. no), history of HTN (yes vs. no), hypercholesterolemia (yes vs. no), diabetes (yes vs. no), family history of MI (no, before age 60 y, after age 60 y), history of prior CVD (yes vs. no)
53	Albert 2005 16301356	no	age, time periods, smoking status (never, past, curent), BMI (<22, 22-22.9, 23-24.9, 25-28.9, 29+ kg/m2), alcohol intake (0, <5, 5-14, 15+), menopausal status and postmenopausal hormone use, vigorous to moderate activity (<1, 1-1.9, 2-3.9, 4-6.9, 7+ hours/week), number of times aspirin was used per week (<1, 1-2, 3-6, 7-14, 15+), multivitamin use (yes vs. no), vitamin E supplement use (yes vs. no), history of HTN (yes vs. no), hypercholesterolemia (yes vs. no), diabetes (yes vs. no), family history of MI (no, before age 60 y, after age 60 y), history of prior CVD (yes vs. no)
54	Albert 2005 16301356	no	age, time periods, smoking status (never, past, curent), BMI (<22, 22-22.9, 23-24.9, 25-28.9, 29+ kg/m2), alcohol intake (0, <5, 5-14, 15+), menopausal status and postmenopausal hormone use, vigorous to moderate activity (<1, 1-1.9, 2-3.9, 4-6.9, 7+ hours/week), number of times aspirin was used per week (<1, 1-2, 3-6, 7-14, 15+), multivitamin use (yes vs. no), vitamin E supplement use (yes vs. no), history of HTN (yes vs. no), hypercholesterolemia (yes vs. no), diabetes (yes vs. no), family history of MI (no, before age 60 y, after age 60 y), history of prior CVD (yes vs. no)
55	Albert 2005 16301356	no	age, time periods, smoking status (never, past, curent), BMI (<22, 22-22.9, 23-24.9, 25-28.9, 29+ kg/m2), alcohol intake (0, <5, 5-14, 15+), menopausal status and postmenopausal hormone use, vigorous to moderate activity (<1, 1-1.9, 2-3.9, 4-6.9, 7+ hours/week), number of times aspirin was used per week (<1, 1-2, 3-6, 7-14, 15+), multivitamin use (yes vs. no), vitamin E supplement use (yes vs. no), history of HTN (yes vs. no), hypercholesterolemia (yes vs. no), diabetes (yes vs. no), family history of MI (no, before age 60 y, after age 60 y), history of prior CVD (yes vs. no)
56	Albert 2005 16301356	no	age, time periods, smoking status (never, past, curent), BMI (<22, 22-22.9, 23-24.9, 25-28.9, 29+ kg/m2), alcohol intake (0, <5, 5-14, 15+), menopausal status and postmenopausal hormone use, vigorous to moderate activity (<1, 1-1.9, 2-3.9, 4-6.9, 7+ hours/week), number of times aspirin was used per week (<1, 1-2, 3-6, 7-14, 15+), multivitamin use (yes vs. no), vitamin E supplement use (yes vs. no), history of HTN (yes vs. no), hypercholesterolemia (yes vs. no), diabetes (yes vs. no), family history of MI (no, before age 60 y, after age 60 y), history of prior CVD (yes vs. no)
57	Albert 2005 16301356	no	age, time periods, smoking status (never, past, curent), BMI (<22, 22-22.9, 23-24.9, 25-28.9, 29+ kg/m2), alcohol intake (0, <5, 5-14, 15+), menopausal status and postmenopausal hormone use, vigorous to moderate activity (<1, 1-1.9, 2-3.9, 4-6.9, 7+ hours/week), number of times aspirin was used per week (<1, 1-2, 3-6, 7-14, 15+), multivitamin use (yes vs. no), vitamin E supplement use (yes vs. no), history of HTN (yes vs. no), hypercholesterolemia (yes vs. no), diabetes (yes vs. no), family history of MI (no, before age 60 y, after age 60 y), history of prior CVD (yes vs. no)

Row	Study PMID	Quantile	n3 units	Quantile low	Quantile median	Quantile high	Metric	n Cases	N quantile	Person Years	Estimate	CI low	CI high	Comparison	P value
39	Iso 2006 16401768	Qt3	g/d	nd	0.9 (mean)	nd	HR	9	nd	95258	1.04	0.34	3.16	Companson	1 value
		Q.O	9,4		ole (mean)			Č		33233		0.0.	0.10		
40	Iso 2006 16401768	Qt4	g/d	nd	1.3 (mean)	nd	HR	9	nd	91435	1.03	0.32	3.37		
41	Iso 2006 16401768	Qt5	g/d	nd	2.1 (mean)	nd	HR	12	nd	92062	1.24	0.39	3.98		
42	Albert 1998 942039	T1	g/mo	<0.3	nd	nd	RR	9	nd	7715	1				0.21
43	Albert 1998 942039	T2	g/mo	0.3	nd	2.7	RR	40	nd	65223	0.58	0.28	1.21		
44	Albert 1998 942039	Т3	g/mo	2.7	nd	4.9	RR	19	nd	56083	0.34	0.15	0.75		
45	Albert 1998 942039	T4	g/mo	4.9	nd	7.4	RR	37	nd	61936	0.6	0.29	1.27		
46	Albert 1998 942039	T5	g/mo	nd	nd	>=7.4	RR	28	nd	62820	0.43	0.2	0.93		
48	Subgroup analyses														
49	Albert 2005 16301356	Qt1	% kcal	nd	0.35	nd	RR	13	nd	13007	Reference group			P trend	0.33
50	Albert 2005 16301356	Qt2	% kcal	nd	0.43	nd	RR	9	nd	12965	0.68	0.28	1.64		
51	Albert 2005 16301356	Qt3	% kcal	nd	0.49	nd	RR	6	nd	12936	0.38	0.14	1.06		
52	Albert 2005 16301356	Qt4	% kcal	nd	0.58	nd	RR	10	nd	12907	0.76	0.3	1.88		
53	Albert 2005 16301356	Qt5	% kcal	nd	0.72	nd	RR	9	nd	12841	0.53	0.19	1.45		
54	Albert 2005 16301356	Qt1	% kcal	nd	0.37	nd	RR	40	nd	252241	Reference group			P trend	0.03
55	Albert 2005 16301356	Qt2	% kcal	nd	0.45	nd	RR	34	nd	251981	0.89	0.56	1.41		
56	Albert 2005 16301356	Qt3	% kcal	nd	0.52	nd	RR	34	nd	251869	0.86	0.54	1.39		
57	Albert 2005 16301356	Qt4	% kcal	nd	0.6	nd	RR	24	nd	251644	0.6	0.35	1.03		

# SUDDEN CORONARY DEATH Page 32 of 308

	0. 1. 0.110										
Row	Study PMID	Study Name	Outcome	Outcome Definition	Population Type	Population	Subgroup	Cases Total/N Total (Rate %)	Followup	n3 FA	n3 measure
58	Albert 2005 16301356	Nurses' Health Study	SCD	nd	Healthy	Healthy 34-59 yo female nurses	No CVD	159/nd (0.3)	18 y	ALA	Intake
59	Mozaffarian_2005_15630029	Health Professional Follow-up Study	SCD	nd	Healthy	Healthy 40-75 y/o men	men	218/45722 (0.48)	14y	EPA+DHA	Intake
60	Mozaffarian_2005_15630029	Health Professional Follow-up Study	SCD	nd	Healthy	Healthy 40-75 y/o men	men	218/45722 (0.48)	14y	EPA+DHA	Intake
61	Mozaffarian_2005_15630029	Health Professional Follow-up Study	SCD	nd	Healthy	Healthy 40-75 y/o men	men	218/45722 (0.48)	14y	EPA+DHA	Intake
62	Mozaffarian_2005_15630029	Health Professional Follow-up Study	SCD	nd	Healthy	Healthy 40-75 y/o men	men	218/45722 (0.48)	14y	EPA+DHA	Intake
63	Mozaffarian_2005_15630029	Health Professional Follow-up Study	SCD	nd	Healthy	Healthy 40-75 y/o men	men	218/45722 (0.48)	14y	EPA+DHA	Intake
64	Mozaffarian_2005_15630029	Health Professional Follow-up Study	SCD	nd	Healthy	Healthy 40-75 y/o men	men	218/45722 (0.48)	14y	EPA+DHA	Intake
65	Mozaffarian_2005_15630029	Health Professional Follow-up Study	SCD	nd	Healthy	Healthy 40-75 y/o men	men	218/45722 (0.48)	14y	ALA	Intake
66	Mozaffarian_2005_15630029	Health Professional Follow-up Study	SCD	nd	Healthy	Healthy 40-75 y/o men	men	218/45722 (0.48)	14y	ALA	Intake
67	Mozaffarian_2005_15630029	Health Professional Follow-up Study	SCD	nd	Healthy	Healthy 40-75 y/o men	men	218/45722 (0.48)	14y	ALA	Intake
68	Mozaffarian_2005_15630029	Health Professional Follow-up Study	SCD	nd	Healthy	Healthy 40-75 y/o men	men	218/45722 (0.48)	14y	ALA	Intake
69	Mozaffarian_2005_15630029	Health Professional Follow-up Study	SCD	nd	Healthy	Healthy 40-75 y/o men	men	218/45722 (0.48)	14y	ALA	Intake

# SUDDEN CORONARY DEATH Page 33 of 308

Row	Study PMID	Supplement	Adjustments
58	Albert 2005 16301356	no	age, time periods, smoking status (never, past, curent), BMI (<22, 22-22.9, 23-24.9, 25-28.9, 29+ kg/m2), alcohol intake (0, <5, 5-14, 15+), menopausal status and postmenopausal hormone use, vigorous to moderate activity (<1, 1-1.9, 2-3.9, 4-6.9, 7+ hours/week), number of times aspirin was used per week (<1, 1-2, 3-6, 7-14, 15+), multivitamin use (yes vs. no), vitamin E supplement use (yes vs. no), history of HTN (yes vs. no), hypercholesterolemia (yes vs. no), diabetes (yes vs. no), family history of MI (no, before age 60 y, after age 60 y), history of prior CVD (yes vs. no)
59	Mozaffarian_2005_15630029	no	age (5-year categories); body mass index (quintiles); smoking (5 categories); physical activity (quintiles); history of diabetes, hypertension, or hypercholesterolemia; aspirin use; alcohol use (quintiles); and intake of protein, saturated fat, dietary fiber, monounsaturated fat, trans fatty acids, total calories, and ALA (each in quintiles).
60	Mozaffarian_2005_15630029	no	age (5-year categories); body mass index (quintiles); smoking (5 categories); physical activity (quintiles); history of diabetes, hypertension, or hypercholesterolemia; aspirin use; alcohol use (quintiles); and intake of protein, saturated fat, dietary fiber, monounsaturated fat, trans fatty acids, total calories, and ALA (each in quintiles).
61	Mozaffarian_2005_15630029	no	age (5-year categories); body mass index (quintiles); smoking (5 categories); physical activity (quintiles); history of diabetes, hypertension, or hypercholesterolemia; aspirin use; alcohol use (quintiles); and intake of protein, saturated fat, dietary fiber, monounsaturated fat, trans fatty acids, total calories, and ALA (each in quintiles).
62	Mozaffarian_2005_15630029	no	age (5-year categories); body mass index (quintiles); smoking (5 categories); physical activity (quintiles); history of diabetes, hypertension, or hypercholesterolemia; aspirin use; alcohol use (quintiles); and intake of protein, saturated fat, dietary fiber, monounsaturated fat, trans fatty acids, total calories, and ALA (each in quintiles).
63	Mozaffarian_2005_15630029	no	age (5-year categories); body mass index (quintiles); smoking (5 categories); physical activity (quintiles); history of diabetes, hypertension, or hypercholesterolemia; aspirin use; alcohol use (quintiles); and intake of protein, saturated fat, dietary fiber, monounsaturated fat, trans fatty acids, total calories, and ALA (each in quintiles).
64	Mozaffarian_2005_15630029	no	age (5-year categories); body mass index (quintiles); smoking (5 categories); physical activity (quintiles); history of diabetes, hypertension, or hypercholesterolemia; aspirin use; alcohol use (quintiles); and intake of protein, saturated fat, dietary fiber, monounsaturated fat, trans fatty acids, total calories, and ALA (each in quintiles).
65	Mozaffarian_2005_15630029	no	age (5-year categories); body mass index (quintiles); smoking (5 categories); physical activity (quintiles); history of diabetes, hypertension, or hypercholesterolemia; aspirin use; alcohol use (quintiles); and intake of protein, saturated fat, dietary fiber, monounsaturated fat, trans fatty acids, total calories, and ALA (each in quintiles).
66	Mozaffarian_2005_15630029	no	age (5-year categories); body mass index (quintiles); smoking (5 categories); physical activity (quintiles); history of diabetes, hypertension, or hypercholesterolemia; aspirin use; alcohol use (quintiles); and intake of protein, saturated fat, dietary fiber, monounsaturated fat, trans fatty acids, total calories, and ALA (each in quintiles).
67	Mozaffarian_2005_15630029	no	age (5-year categories); body mass index (quintiles); smoking (5 categories); physical activity (quintiles); history of diabetes, hypertension, or hypercholesterolemia; aspirin use; alcohol use (quintiles); and intake of protein, saturated fat, dietary fiber, monounsaturated fat, trans fatty acids, total calories, and ALA (each in quintiles).
68	Mozaffarian_2005_15630029	no	age (5-year categories); body mass index (quintiles); smoking (5 categories); physical activity (quintiles); history of diabetes, hypertension, or hypercholesterolemia; aspirin use; alcohol use (quintiles); and intake of protein, saturated fat, dietary fiber, monounsaturated fat, trans fatty acids, total calories, and ALA (each in quintiles).
69	Mozaffarian_2005_15630029	no	age (5-year categories); body mass index (quintiles); smoking (5 categories); physical activity (quintiles); history of diabetes, hypertension, or hypercholesterolemia; aspirin use; alcohol use (quintiles); and intake of protein, saturated fat, dietary fiber, monounsaturated fat, trans fatty acids, total calories, and ALA (each in quintiles).

## SUDDEN CORONARY DEATH Page 34 of 308

Row	Study PMID	Quantile	n3 units	Quantile low	Quantile median	Quantile high	Metric	n Cases	N quantile	Person Years	Estimate	CI low	CI high	Comparison	P value
58	Albert 2005 16301356	Qt5	% kcal	nd	0.74	nd	RR	27	nd	251727	0.59	0.34	1.02		
9	Mozaffarian_2005_15630029	<median< td=""><td>mg/d</td><td>nd</td><td>n-6&lt;11.2 g/d</td><td>250</td><td>HR</td><td>127</td><td>23111</td><td>nd</td><td>Ref</td><td></td><td></td><td></td><td></td></median<>	mg/d	nd	n-6<11.2 g/d	250	HR	127	23111	nd	Ref				
60	Mozaffarian_2005_15630029	>Median	mg/d	250	n-6>11.2 g/d	nd	HR	91	22611	nd	0.65	0.47	0.88		
61	Mozaffarian_2005_15630029	<median< td=""><td>mg/d</td><td>nd</td><td>n-6&lt;11.2 g/d</td><td>250</td><td>RR</td><td>62</td><td>10982</td><td>nd</td><td>Ref</td><td></td><td></td><td>P low vs high n-6 intake</td><td>0.13</td></median<>	mg/d	nd	n-6<11.2 g/d	250	RR	62	10982	nd	Ref			P low vs high n-6 intake	0.13
62	Mozaffarian_2005_15630029	<median< td=""><td>mg/d</td><td>nd</td><td>n-6&gt;11.2 g/d</td><td>250</td><td>RR</td><td>65</td><td>12129</td><td>nd</td><td>0.76</td><td>0.52</td><td>1.11</td><td></td><td></td></median<>	mg/d	nd	n-6>11.2 g/d	250	RR	65	12129	nd	0.76	0.52	1.11		
3	Mozaffarian_2005_15630029	>Median	mg/d	250	n-6<11.2 g/d	nd	RR	46	11880	nd	0.52	0.34	0.79		
64	Mozaffarian_2005_15630029	>Median	mg/d	250	n-6>11.2 g/d	nd	RR	45	10731	nd	0.6	0.39	0.93		
65	Mozaffarian_2005_15630029	All	mg/d	nd	per 1 g/d increase	nd	HR				1.15	0.69	1.93		
66	Mozaffarian_2005_15630029	<median< td=""><td>mg/d</td><td>nd</td><td>n-6&lt;11.2 g/d</td><td>1080</td><td>RR</td><td>66</td><td>14462</td><td>nd</td><td>Ref</td><td></td><td></td><td>P low vs high n-6 intake</td><td>0.38</td></median<>	mg/d	nd	n-6<11.2 g/d	1080	RR	66	14462	nd	Ref			P low vs high n-6 intake	0.38
67	Mozaffarian_2005_15630029	<median< td=""><td>mg/d</td><td>nd</td><td>n-6&gt;11.2 g/d</td><td>1080</td><td>RR</td><td>36</td><td>8385</td><td>nd</td><td>0.88</td><td>0.56</td><td>1.36</td><td></td><td></td></median<>	mg/d	nd	n-6>11.2 g/d	1080	RR	36	8385	nd	0.88	0.56	1.36		
68	Mozaffarian_2005_15630029	>Median	mg/d	1080	n-6<11.2 g/d	nd	RR	42	8400	nd	0.95	0.64	1.43		
69	Mozaffarian_2005_15630029	>Median	mg/d	1080	n-6>11.2 g/d	nd	RR	74	14475	nd	0.93	0.64	1.35		